Comparison of the exposure time dependence of the activities of synthetic ozonide antimalarials and dihydroartemisinin against K13 wild-type and mutant Plasmodium falciparum Strains

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4501-4510

  Yang, Tuo ^a   Xie, Stanley C ^a   Cao, Pengxing ^b   Giannangelo, Carlo ^c   McCaw, James ^b,d,e   Creek, Darren J ^c   Charman, Susan A ^c   Klonis, Nectarios ^a   Tilley, Leann ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEFENOMEL; ARTEROLANE; DIHYDROARTEMISININ; 1,2,4-TRIOXANE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; HETEROCYCLIC COMPOUND;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CAMBODIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; IN VITRO STUDY; LC50; NONHUMAN; PARASITE LOAD; PARASITE VIABILITY; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PLASMODIUM FALCIPARUM; PLASMODIUM FALCIPARUM K13; PRIORITY JOURNAL; PROCESS OPTIMIZATION; DRUG EFFECTS; DRUG SENSITIVITY;

ANTIMALARIALS; ARTEMISININS; HETEROCYCLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM;

EID: 84979517803     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00574-16     Document Type: Article

References (47)

1. World Health Organization. 2015. World malaria report, 2015. WHO, Geneva, Switzerland. http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/.
2. Enserink M. 2010. Malaria's drug miracle in danger. Science 328:844-846. http://dx.doi.org/10.1126/science.328.5980.844.
3. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. 2014. Malaria. Lancet 383:723-735. http://dx.doi.org/10.1016/S0140-6736(13)60024-0.
4. White NJ. 2013. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother 57: 5792-5807. http://dx.doi.org/10.1128/AAC.00287-13.
5. Lubell Y, Dondorp A, Guerin PJ, Drake T, Meek S, Ashley E, Day NP, White NJ, White LJ. 2014. Artemisinin resistance - modelling the potential human and economic costs. Malar J 13:452. http://dx.doi.org/10.1186/1475-2875-13-452.
6. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, Lin K, Kyaw MP, Plewes K, Faiz MA, Dhorda M, Cheah PY, Pukrittayakamee S, Ashley EA, Anderson TJ, Nair S, McDew-White M, Flegg JA, Grist EP, Guerin P, Maude RJ, Smithuis F, Dondorp AM, Day NP, Nosten F, White NJ, Woodrow CJ. 2015. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 15:415-421. http://dx.doi.org/10.1016/S1473-3099(15)70032-0.
7. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50-55. http://dx.doi.org/10.1038/nature12876.
8. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM. 2016. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 16:357-365. http://dx.doi.org/10.1016/S1473-3099(15)00487-9.
9. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul M, Sia-ngam P, Kuntawunginn W, Arsanok M, Buathong N, Chaorattanakawee S, Gosi P, Ta-aksorn W, Chanarat N, Sundrakes S, Kong N, Heng TK, Nou S, Teja-isavadharm P, Pichyangkul S, Phann ST, Balasubramanian S, Juliano JJ, Meshnick SR, Chour CM, Prom S, Lanteri CA, Lon C, Saunders DL. 2015. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15:683-691. http://dx.doi.org/10.1016/S1473-3099(15)70049-6.
10. Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. 2015. Malaria medicines: a glass half full? Nat Rev Drug Discov 14:424-442. http://dx.doi.org/10.1038/nrd4573.
11. Patra N, Srivastava AK. 2015. Use of model-based nutrient feeding for improved production of artemisinin by hairy roots of Artemisia annua in a modified stirred tank bioreactor. Appl Biochem Biotechnol 177:373-388. http://dx.doi.org/10.1007/s12010-015-1750-8.
12. Paddon CJ, Keasling JD. 2014. Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat Rev Microbiol 12:355-367. http://dx.doi.org/10.1038/nrmicro3240.
13. Zhang Y, Nowak G, Reed DW, Covello PS. 2011. The production of artemisinin precursors in tobacco. Plant Biotechnol J 9:445-454. http://dx.doi.org/10.1111/j.1467-7652.2010.00556.x.
14. UNITAID. 2014. Demand forecast for artemisinin-based combination therapies (ACTs) in 2013-2014. UNITAID, Vernier, Switzerland.
15. O'Neill PM, Barton VE, Ward SA. 2010. The molecular mechanism of action of artemisinin. The debate continues. Molecules 15:1705-1721. http://dx.doi.org/10.3390/molecules15031705.
16. Vennerstrom JL, Fu HN, Ellis WY, Ager AL, Jr, Wood JK, Andersen SL, Gerena L, Milhous WK. 1992. Dispiro-1,2,4,5-tetraoxanes: a new class of antimalarial peroxides. J Med Chem 35:3023-3027. http://dx.doi.org/10.1021/jm00094a015.
17. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN. 2004. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900-904. http://dx.doi.org/10.1038/nature02779.
18. Dong Y, Chollet J, Matile H, Charman SA, Chiu FC, Charman WN, Scorneaux B, Urwyler H, Santo Tomas J, Scheurer C, Snyder C, Dorn A, Wang X, Karle JM, Tang Y, Wittlin S, Brun R, Vennerstrom JL. 2005. Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes. J Med Chem 48:4953-4961. http://dx.doi.org/10.1021/jm049040u.
19. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL. 2011. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 108:4400-4405. http://dx.doi.org/10.1073/pnas.1015762108.
20. Kaiser M, Wittlin S, Nehrbass-Stuedli A, Dong Y, Wang X, Hemphill A, Matile H, Brun R, Vennerstrom JL. 2007. Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). Antimicrob Agents Chemother 51:2991-2993. http://dx.doi.org/10.1128/AAC.00225-07.
21. Valecha N, Looareesuwan S, Martensson A, Abdulla SM, Krudsood S, Tangpukdee N, Mohanty S, Mishra SK, Tyagi PK, Sharma SK, Moehrle J, Gautam A, Roy A, Paliwal JK, Kothari M, Saha N, Dash AP, Bjorkman A. 2010. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 51:684-691. http://dx.doi.org/10.1086/655831.
22. Valecha N, Krudsood S, Tangpukdee N, Mohanty S, Sharma SK, Tyagi PK, Anvikar A, Mohanty R, Rao BS, Jha AC, Shahi B, Singh JP, Roy A, Kaur P, Kothari M, Mehta S, Gautam A, Paliwal JK, Arora S, Saha N. 2012. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis 55:663-671. http://dx.doi.org/10.1093/cid/cis475.
23. Gautam A, Ahmed T, Sharma P, Varshney B, Kothari M, Saha N, Roy A, Moehrle JJ, Paliwal J. 2011. Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P. falciparum malaria. J Clin Pharmacol 51:1519-1528. http://dx.doi.org/10.1177/0091270010385578.
24. Saha N, Moehrle JJ, Zutshi A, Sharma P, Kaur P, Iyer SS. 2014. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. J Clin Pharmacol 54:386-393. http://dx.doi.org/10.1002/jcph.232.
25. Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, Duparc S, Macintyre F, Baker M, Mohrle JJ. 2016. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis 16:61-69. http://dx.doi.org/10.1016/S1473-3099(15)00320-5.
26. Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL. 2013. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol 75:524-537. http://dx.doi.org/10.1111/j.1365-2125.2012.04368.x.
27. Tang Y, Dong Y, Vennerstrom JL. 2004. Synthetic peroxides as antimalarials. Med Res Rev 24:425-448. http://dx.doi.org/10.1002/med.10066.
28. Fugi MA, Wittlin S, Dong Y, Vennerstrom JL. 2010. Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals. Antimicrob Agents Chemother 54: 1042-1046. http://dx.doi.org/10.1128/AAC.01305-09.
29. Foley M, Deady LW, Ng K, Cowman AF, Tilley L. 1994. Photoaffinity labeling of chloroquine-binding proteins in Plasmodium falciparum. J Biol Chem 269:6955-6961.
30. Ranford-Cartwright LC, Sinha A, Humphreys GS, Mwangi JM. 2010. New synchronization method for Plasmodium falciparum. Malar J 9:170. http://dx.doi.org/10.1186/1475-2875-9-170.
31. Xie SC, Dogovski C, Kenny S, Tilley L, Klonis N. 2014. Optimal assay design for determining the in vitro sensitivity of ring stage Plasmodium falciparum to artemisinins. Int J Parasitol 44:893-899. http://dx.doi.org/10.1016/j.ijpara.2014.07.008.
32. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, Tilley L. 2011. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A 108:11405-11410. http://dx.doi.org/10.1073/pnas.1104063108.
33. Fu Y, Tilley L, Kenny S, Klonis N. 2010. Dual labeling with a far red probe permits analysis of growth and oxidative stress in P. falciparum-infected erythrocytes. Cytometry A 77:253-263. http://dx.doi.org/10.1002/cyto.a.20856.
34. Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, Tilley L. 2013. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A 110:5157-5162. http://dx.doi.org/10.1073/pnas.1217452110.
35. Dogovski C, Xie SC, Burgio G, Bridgford J, Mok S, McCaw JM, Chotivanich K, Kenny S, Gnadig N, Straimer J, Bozdech Z, Fidock DA, Simpson JA, Dondorp AM, Foote S, Klonis N, Tilley L. 2015. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol 13:e1002132. http://dx.doi.org/10.1371/journal.pbio.1002132.
36. Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD, Urnov FD, Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM, Menard D, Fidock DA. 2015. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347: 428-431. http://dx.doi.org/10.1126/science.1260867.
37. Xie SC, Dogovski C, Hanssen E, Chiu F, Yang T, Crespo MP, Stafford C, Batinovic S, Teguh S, Charman S, Klonis N, Tilley L. 2016. Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins. J Cell Sci 129:406-416. http://dx.doi.org/10.1242/jcs.178830.
38. Wang X, Creek DJ, Schiaffo CE, Dong Y, Chollet J, Scheurer C, Wittlin S, Charman SA, Dussault PH, Wood JK, Vennerstrom JL. 2009. Spiroadamantyl 1,2,4-trioxolane, 1,2,4-trioxane, and 1,2,4-trioxepane pairs: relationship between peroxide bond iron(II) reactivity, heme alkylation efficiency, and antimalarial activity. Bioorg Med Chem Lett 19:4542-4545. http://dx.doi.org/10.1016/j.bmcl.2009.07.013.
39. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S, Leang R, Ringwald P, Dondorp AM, Tripura R, Benoit-Vical F, Berry A, Gorgette O, Ariey F, Barale JC, Mercereau-Puijalon O, Menard D. 2013. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 57:914-923. http://dx.doi.org/10.1128/AAC.01868-12.
40. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455-467. http://dx.doi.org/10.1056/NEJMoa0808859.
41. Meshnick SR. 2003. Artemisinin and heme. Antimicrob Agents Chemother 47:2712. http://dx.doi.org/10.1128/AAC.47.8.2712-2713.2003.
42. Wang J, Zhang C-J, Chia W, Loh CCY, Li Z, Lee YM, He Y, Yuan L-X, Lim TK, Liu M, Liew CX, Lee YQ, Zhang J, Lu N, Lim CT, Hua Z-C, Liu B, Shen H-M, Tan KSW, Lin Q. 2015. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun 6:10111. http://dx.doi.org/10.1038/ncomms10111.
43. Meshnick SR, Taylor TE, Kamchonwongpaisan S. 1996. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 60:301-315.
44. Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, Chotivanich K, Imwong M, Pukrittayakamee S, Dhorda M, Nguon C, Lim P, Amaratunga C, Suon S, Hien TT, Htut Y, Faiz MA, Onyamboko MA, Mayxay M, Newton PN, Tripura R, Woodrow CJ, Miotto O, Kwiatkowski DP, Nosten F, Day NP, Preiser PR, White NJ, Dondorp AM, Fairhurst RM, Bozdech Z. 2015. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347:431-435. http://dx.doi.org/10.1126/science.1260403.
45. Smith DA, Di L, Kerns EH. 2010. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929-939. http://dx.doi.org/10.1038/nrd3287.
46. Tucker MS, Mutka T, Sparks K, Patel J, Kyle DE. 2012. Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. Antimicrob Agents Chemother 56:302-314. http://dx.doi.org/10.1128/AAC.05540-11.
47. Hott A, Casandra D, Sparks KN, Morton LC, Castanares GG, Rutter A, Kyle DE. 2015. Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes. Antimicrob Agents Chemother 59:3156-3167. http://dx.doi.org/10.1128/AAC.00197-15.